UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36007 PHYSICIANS REALTY TRUST (Exact Name of Registrant as Specified in Its Charter) Maryland 46-2519850 (State or Other Jurisdiction of Incorpora ...

Physicians Realty Trust (DOC) reported $135.47 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 2.2%. EPS of $0.26 for the same period compares to $0.05 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $137.99 million, representing a surprise of -1.82%. The company has not delivered EPS surprise, with the consensus EPS estimate being $0.26.While investors closely watch year-over-year changes in headline numbers -- revenue and earnin ...

Physicians Realty Trust (DOC) came out with quarterly funds from operations (FFO) of $0.26 per share, in line with the Zacks Consensus Estimate. This compares to FFO of $0.26 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this health care real estate investment trust would post FFO of $0.25 per share when it actually produced FFO of $0.25, delivering no surprise.Over the last four quarters, the company has not been able to surpass consensus FFO e ...

DENVER & MILWAUKEE--(BUSINESS WIRE)--Healthpeak Properties, Inc. (NYSE: PEAK) (“Healthpeak”) and Physicians Realty Trust (NYSE: DOC) (“Physicians Realty Trust”) today announced that Healthpeak stockholders and Physicians Realty Trust shareholders have voted to approve the proposals necessary for the closing of the proposed merger at their respective special meetings held virtually today, February 21, 2024. The transaction is expected to close on or about March 1, 2024, subject to the satisfaction or waiver ...

Financial Performance - Total revenue for Q4 2023 was $135.5 million, an increase of 2.2% from Q4 2022[3] - Net income for Q4 2023 was $7.1 million, a decrease of 40.1% compared to Q4 2022, with diluted earnings per share of $0.03[4] - Normalized Funds From Operations (FFO) for Q4 2023 was $64.1 million, or $0.26 per share on a fully diluted basis[6] - Total revenues for Q4 2023 were $135.472 million, a 2.9% increase from $132.565 million in Q4 2022[23] - Net income for Q4 2023 was $7.122 million, down 40.1% from $11.881 million in Q4 2022[23] - Rental and related revenues for the year ended December 31, 2023, were $528.093 million, compared to $515.373 million in 2022, reflecting a 2.5% increase[23] - Basic earnings per share for Q4 2023 were $0.03, down from $0.05 in Q4 2022[29] - Total revenue for the year ended December 31, 2023, was $43.767 million, down from $110.036 million in 2022, representing a decline of 60.2%[30] Investments and Expenses - The company completed $47.4 million in investments during Q4 2023, including funding of previous loan commitments[4] - The company recorded merger and transaction-related expenses of $6.9 million in 2023 related to the proposed merger with Healthpeak[23] - General and administrative expenses decreased to $7.623 million in Q4 2023 from $9.809 million in Q4 2022, a reduction of 22.3%[30] - Merger and transaction-related expenses amounted to $6.934 million in 2023, primarily due to the proposed merger with Healthpeak[30] Portfolio and Leasing - The consolidated portfolio was approximately 94.3% leased as of December 31, 2023[3] - The weighted average leasing spread for the year ended 2023 was 4.2% with a 74% retention rate[4] - Outpatient Medical Same-Store Cash Net Operating Income growth was 1.0% year-over-year for Q4 2023[8] - Outpatient Medical Same-Store Cash NOI for Q4 2023 was $84.555 million, up from $83.734 million in Q4 2022, an increase of 1.0%[30] Cash and Assets - Total assets as of December 31, 2023, were $5.156 billion, compared to $5.097 billion as of December 31, 2022, representing a 1.2% increase[27] - Total liabilities increased to $2.266 billion in 2023 from $2.100 billion in 2022, a rise of 7.9%[27] - Cash and cash equivalents increased significantly to $156.779 million in 2023 from $7.730 million in 2022[27] Earnings and Dividends - A quarterly dividend of $0.23 per share was declared for Q4 2023, paid on January 18, 2024[13] - The company declared dividends of $0.23 per common share for both Q4 2023 and Q4 2022[29] Other Financial Metrics - EBITDAre for Q4 2023 was $77.164 million, down from $82.958 million in Q4 2022, reflecting a decrease of 7.0%[32] - Adjusted EBITDAre increased to $89.984 million in Q4 2023 from $87.914 million in Q4 2022, an increase of 2.4%[32] - Cash NOI for the year was $371.506 million, compared to $367.248 million in 2022, showing a growth of 1.0%[30] - Interest expense rose to $21.514 million in Q4 2023, compared to $19.878 million in Q4 2022, an increase of 8.2%[32] - The company recorded a non-cash share compensation expense of $3.386 million in Q4 2023, slightly up from $3.272 million in Q4 2022[32] Mergers and Acquisitions - The company announced an all-stock merger with Healthpeak Properties, expected to close on or about March 1, 2024[2]

DENVER--(BUSINESS WIRE)--Healthpeak Properties, Inc. (NYSE: PEAK) (“Healthpeak”) today announced, in connection with its previously announced agreement to merge with Physicians Realty Trust (NYSE: DOC) (“Physicians Realty Trust” or “DOC”), that it and Healthpeak OP, LLC (“Healthpeak OP”), a direct subsidiary of Healthpeak, have commenced a consent solicitation to certain proposed amendments to each of the supplemental indentures to the Senior Indenture (each an “Indenture”) governing the following outstandi ...

Healthpeak Properties, Inc. (PEAK) Q4 2023 Earnings Conference Call February 9, 2024 10:00 AM ET Andrew Johns - Senior Vice President, Investor Relations Scott Brinker - President and Chief Executive Officer Pete Scott - Chief Financial Officer John Thomas - Chief Executive Officer, Physicians Realty Trust Scott Bohn - Chief Development Officer and Head, Lab Tom Klaritch - Chief Operating Officer Shawn John - Executive Vice President and Chief Accounting Officer Nick Yulico - Scotiabank Juan Sanabria - BMO ...

NEW YORK, Jan. 26, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers.  Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies.  Kuehn Law is investigating whether the Boards of the below companies 1) acted to maximize shareholder value, 2) failed to disclose material information, and 3) conducted a fair process:  Physicians Realty Trust (NYSE: DOC) click ...

Financial Data and Key Metrics Changes - For Q3 2023, the company reported FFO as Adjusted of $0.45 per share and AFFO of $0.40 per share, with total portfolio same-store growth of 6% [10] - The company increased its FFO as Adjusted and AFFO guidance by two cents at the midpoints to $1.77 and $1.53 respectively [109] Business Line Data and Key Metrics Changes - Outpatient Medical segment reported same-store growth of 3.4%, with 2.2 million square feet of leases signed during the quarter [10] - Lab segment achieved same-store growth of 3.3%, executing 211,000 square feet of leases [10] - Continuing Care Retirement Communities (CCRCs) saw exceptional same-store growth of 32.1%, driven by occupancy gains and margin improvement [12] Market Data and Key Metrics Changes - The outpatient medical sector is expected to continue growing due to senior population growth and high costs of new construction, with demand exceeding supply [104] - The combined company will have a significant presence in high-growth markets such as Dallas, Houston, and Phoenix, enhancing competitive advantages [117] Company Strategy and Development Direction - The merger aims to create a leading real estate platform dedicated to healthcare, focusing on long-term growth and resilience to market conditions [7][19] - The company plans to internalize property management across its medical and lab portfolios, enhancing local market knowledge and relationships [118] - The strategic focus will include outpatient medical acquisitions, new developments with health systems, and capital recycling opportunities [146] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the merger's potential to be accretive to both companies, with expected synergies of $40 million to $60 million [114] - The management highlighted the importance of adapting to the evolving healthcare delivery landscape, emphasizing the need for off-campus facilities [21][139] Other Important Information - The merger is structured as a 100% stock transaction, with no cash changing hands, and is expected to close in the first half of 2024 [112][113] - The combined company will maintain a dividend of $1.20 per share, resulting in an AFFO payout ratio of 80% or below [112] Q&A Session Summary Question: Can you provide additional detail around the synergy components within the $40 million to $60 million? - Management expects the transaction to be accretive to both AFFO and FFO per share, with significant savings from compensation and corporate overhead [43][67] Question: How do you view the combined company's growth opportunities? - The merger is expected to augment the internal growth profile, making it less volatile and more predictable, with increased capabilities in serving clients [44] Question: What is the strategy regarding on-campus versus off-campus facilities? - The company acknowledges a shift towards off-campus facilities to meet healthcare delivery needs, while still valuing on-campus assets [21][126] Question: How will the merger impact the balance sheet and cost of capital? - The combined entity will have a stronger balance sheet with improved liquidity and lower cost of capital, positioning it well for future opportunities [75][120] Question: What are the expectations for the lab business post-merger? - Management remains confident in the lab business, viewing the merger as an opportunity to enhance operational capabilities and capitalize on market conditions [37][78]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36007 PHYSICIANS REALTY TRUST (Exact Name of Registrant as Specified in its Charter) Maryland 46-2519850 (State of Organization) (IRS ...